EE200000764A - 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid - Google Patents

2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid

Info

Publication number
EE200000764A
EE200000764A EEP200000764A EEP200000764A EE200000764A EE 200000764 A EE200000764 A EE 200000764A EE P200000764 A EEP200000764 A EE P200000764A EE P200000764 A EEP200000764 A EE P200000764A EE 200000764 A EE200000764 A EE 200000764A
Authority
EE
Estonia
Prior art keywords
purin
tetrahydrofuran
diol derivatives
diol
derivatives
Prior art date
Application number
EEP200000764A
Other languages
English (en)
Inventor
George Allen David
Peter Charles Cousins Richard
Victoria Geden Joanna
Judith Redgrave Alison
Chan Chuen
Mary Cook Caroline
Cox Brian
Joan Dyke Hazel
Ellis Frank
Hobbs Heather
Swanson Stephen
Edmund Bays David
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000764A publication Critical patent/EE200000764A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200000764A 1998-06-23 1999-06-23 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid EE200000764A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9813565.0A GB9813565D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/004267 WO1999067264A1 (en) 1998-06-23 1999-06-23 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Publications (1)

Publication Number Publication Date
EE200000764A true EE200000764A (et) 2002-04-15

Family

ID=10834254

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000764A EE200000764A (et) 1998-06-23 1999-06-23 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid

Country Status (26)

Country Link
EP (1) EP1090023B1 (et)
JP (1) JP2002518511A (et)
KR (1) KR20010071570A (et)
CN (1) CN1313860A (et)
AP (1) AP2000002013A0 (et)
AT (1) ATE249474T1 (et)
AU (1) AU758979B2 (et)
BR (1) BR9911488A (et)
CA (1) CA2335758A1 (et)
DE (1) DE69911207D1 (et)
EA (1) EA200001223A1 (et)
EE (1) EE200000764A (et)
GB (1) GB9813565D0 (et)
HR (1) HRP20000895A2 (et)
HU (1) HUP0102454A3 (et)
ID (1) ID28219A (et)
IL (1) IL140285A0 (et)
IS (1) IS5774A (et)
NO (1) NO20006521L (et)
NZ (1) NZ508918A (et)
PL (1) PL345097A1 (et)
SK (1) SK19532000A3 (et)
TR (1) TR200100411T2 (et)
WO (1) WO1999067264A1 (et)
YU (1) YU81000A (et)
ZA (1) ZA200007515B (et)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
US6670334B2 (en) 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
CA2460911C (en) 2001-10-01 2011-08-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
SI2391366T1 (sl) 2009-01-29 2013-01-31 Novartis Ag Substituirani benzimidazoli za zdravljenje astrocitomov
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CA2771532C (en) 2009-08-17 2021-03-23 Intellikine, Inc. Heterocyclic compounds and uses thereof
IN2012DN01453A (et) 2009-08-20 2015-06-05 Novartis Ag
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CA2828219A1 (en) 2011-02-25 2012-08-30 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
EP2834246B1 (en) 2012-04-03 2021-07-28 Novartis AG Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1998001459A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Novel n-alkoxyadenine derivatives acting as cytokine inhibitors
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) * 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Also Published As

Publication number Publication date
ATE249474T1 (de) 2003-09-15
DE69911207D1 (de) 2003-10-16
NO20006521D0 (no) 2000-12-20
ID28219A (id) 2001-05-10
TR200100411T2 (tr) 2001-07-23
PL345097A1 (en) 2001-12-03
JP2002518511A (ja) 2002-06-25
HRP20000895A2 (en) 2001-10-31
AU758979B2 (en) 2003-04-03
YU81000A (sh) 2003-10-31
BR9911488A (pt) 2001-03-20
ZA200007515B (en) 2001-12-14
IL140285A0 (en) 2002-02-10
AP2000002013A0 (en) 2000-12-31
GB9813565D0 (en) 1998-08-19
IS5774A (is) 2000-12-15
EP1090023A1 (en) 2001-04-11
CA2335758A1 (en) 1999-12-29
WO1999067264A1 (en) 1999-12-29
HUP0102454A2 (hu) 2002-01-28
HUP0102454A3 (en) 2003-01-28
AU5028199A (en) 2000-01-10
CN1313860A (zh) 2001-09-19
SK19532000A3 (sk) 2001-11-06
EA200001223A1 (ru) 2001-10-22
NO20006521L (no) 2001-02-22
EP1090023B1 (en) 2003-09-10
KR20010071570A (ko) 2001-07-28
NZ508918A (en) 2003-03-28

Similar Documents

Publication Publication Date Title
EE200000768A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
EE200000441A (et) 2-(puriin-9-üül) tetrahüdrofuraan-3,4-diooli derivaadid
EE200000358A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
EE200000764A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
EE9900312A (et) 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
DK1117669T3 (da) Antiviruspurinderivater
DE69920697D1 (de) Adenosinderivate
SI1056759T1 (en) 2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives
GB9909482D0 (en) 2-(Purin-9-yl)-tetahydrofuran-3,4-diol derivatives
ZA991154B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA99689B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.